By The METAvivor Advocacy Team
As the legislative landscape in Washington D.C. shifts with the dawn of the 2026 fiscal year, the metastatic breast cancer (MBC) community finds itself at a critical juncture. For patients living with stage IV breast cancer, policy is not merely an abstract concept; it is a lifeline that dictates access to care, the pace of scientific innovation, and the accuracy of the data used to track the disease. Throughout February, METAvivor has remained at the forefront of this effort, mobilizing advocates nationwide to ensure that the unique needs of the MBC community remain a top priority for federal lawmakers.
The Federal Funding Landscape: Navigating Appropriations and Policy
February began with significant movement on Capitol Hill regarding the federal budget. On February 3, the signing of the Consolidated Appropriations Act of 2026 marked a major milestone for medical research. This package, negotiated through bipartisan efforts in both the House and Senate, provides a critical infusion of resources for the nation’s primary health research institutions.
The legislation secures increased funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention’s (CDC) Division of Cancer Prevention and Control. Crucially, the Advanced Research Projects Agency for Health (ARPA-H) maintained its existing funding levels, ensuring that high-risk, high-reward research continues to receive support.
Perhaps most significant for the breast cancer community is the allocation of $145 million to the Department of Defense (DOD) Congressionally Directed Medical Research Program (CDMRP) for breast cancer. This represents a $15 million increase over the Fiscal Year (FY) 2025 levels, a testament to the persistent pressure applied by advocacy groups like METAvivor. This funding is vital for supporting innovative, peer-reviewed research that often fills gaps left by larger federal agencies.
However, the budget process has not been without its turbulence. The Department of Homeland Security (DHS) currently remains the only federal agency without approved FY26 funding. Following an impasse that led to a missed deadline on February 13, a partial government shutdown has impacted various DHS programs. While entities such as the Coast Guard and TSA are currently affected, it is worth noting that Immigration and Customs Enforcement (ICE) remains funded under the broader appropriations bill enacted earlier this year.
Preparing for FY27
Even as the ink dries on the 2026 budget, the legislative calendar is already pivoting toward the 2027 fiscal year. Congressional offices have begun distributing internal guidelines for appropriations requests, and the House and Senate Appropriations Committees are expected to announce formal submission deadlines in the coming weeks. With the President’s FY27 budget request anticipated for late March or early April—a slightly delayed schedule compared to historical norms—METAvivor is acting early. By aligning with coalition partners like the AdHoc Group on Healthcare Funding and One Voice Against Cancer (OVAC), METAvivor is submitting unified requests to ensure that our message of increased, stable research funding is amplified across the healthcare stakeholder community.
GroundSwell: A Virtual Force for Change
The cornerstone of METAvivor’s February efforts was the launch of the third annual GroundSwell Virtual Advocacy Event. Running from February 23 through March 6, this initiative serves as a digital town square, allowing over 100 advocates to bring the lived experience of metastatic breast cancer directly to congressional offices.
The logistical complexity of coordinating such an event requires rigorous preparation. In the weeks leading up to the launch, METAvivor facilitated comprehensive training webinars for all participants, with specialized sessions for "State Captains"—the grassroots leaders responsible for organizing state-level outreach. To ensure that every meeting is as effective as possible, the advocacy team provided a suite of digital resources, including:
- Targeted Fact Sheets: Summarizing the legislative priorities and the specific impact of MBC.
- Draft Scripts and Templates: Providing professional, concise templates for meeting requests and follow-up correspondence.
- Legislative Directories: A custom, state-by-state database mapping advocates to their specific Representatives and Senators, along with direct contact information for healthcare staffers.
Following the meetings, participants are encouraged to submit feedback via a post-meeting survey. This data is vital for METAvivor’s internal tracking, allowing the organization to identify which congressional offices are "champions" for the cause and which require additional education and follow-up.
Legislative Priorities: Tracking the Bills
METAvivor’s legislative agenda is focused on removing barriers to care and ensuring equitable treatment for those with advanced-stage cancer. Progress is measurable, though the work remains long-term.
Metastatic Breast Cancer Access to Care Act (H.R. 2048 / S. 3442)
This flagship legislation continues to gain momentum. The House version, H.R. 2048, has now secured 214 cosponsors, representing a strong bipartisan consensus with 154 Democrats and 60 Republicans. The addition of 12 new Republican cosponsors in February is a promising indicator of the bill’s broad appeal. In the Senate, S. 3442, introduced last December, has seen a steady increase in support, moving from three to five cosponsors.
The Cancer Drug Parity Act
This critical piece of legislation, which aims to ensure that oral cancer medications are covered at a level comparable to intravenous treatments, currently boasts 26 House cosponsors. METAvivor is actively working to facilitate the re-introduction of a Senate companion bill, recognizing that parity in drug coverage is an essential component of reducing the financial toxicity of an MBC diagnosis.
Data and Agency Engagement: The SEER Initiative
A major strategic focus for the spring of 2026 is the National Cancer Institute’s SEER (Surveillance, Epidemiology, and End Results) Cancer Registry. For too long, the registry has struggled to capture the full picture of metastatic disease, often failing to differentiate between patients diagnosed with metastatic disease initially (de novo) and those who progress later.
In February, METAvivor initiated a productive dialogue with the North American Association of Central Cancer Registries (NAACCR). The goal is to develop a policy framework that supports the modernization of SEER, specifically targeting how it tracks metastatic recurrence. By working in tandem with the Alliance for Breast Cancer Policy, METAvivor is elevating this issue to ensure that national data collection reflects the actual prevalence and trajectory of MBC, which in turn informs better clinical guidelines and research funding allocation.
Strengthening the Advocacy Infrastructure
Effective advocacy requires more than passion; it requires robust technology and streamlined processes. METAvivor is currently conducting a thorough audit of its digital advocacy tools. Following an initial review in January, the Advocacy Committee co-chairs participated in a demonstration of "Voter Voice," a sophisticated digital advocacy platform.
The evaluation process is rigorous. The leadership team is weighing whether to integrate this platform with existing systems to optimize the ease with which advocates can contact their representatives. The objective is to create a "frictionless" experience for the volunteer advocate, allowing them to focus on sharing their stories rather than managing complex technological workflows.
Looking Toward the Future
As we move into March and beyond, the roadmap for METAvivor’s advocacy efforts is clear. The immediate priority is the successful conclusion of the GroundSwell event and the subsequent follow-up with congressional offices to solidify commitments made during those meetings.
Looking further ahead, the organization is deep in the planning stages for the Thriving Together: 2026 Conference on Metastatic Breast Cancer. This conference will serve as a hub for both medical education and advocacy training, providing a platform to connect clinicians, researchers, and patients.
The fight against metastatic breast cancer is a marathon, not a sprint. The legislative wins of February—including the increased DOD funding—demonstrate that when the MBC community speaks with one voice, Capitol Hill listens. METAvivor remains committed to the relentless pursuit of policies that extend and improve the lives of every patient navigating this disease. Through coalition building, data-driven strategy, and the tireless energy of our advocates, we are moving the needle toward a future where metastatic breast cancer is no longer a terminal diagnosis.
For more information on how to get involved in upcoming advocacy efforts, please visit the METAvivor website or contact your local State Captain.
About the Author
